SilverCloud Health, a leading digital mental health platform, together with a group of international mental health stakeholders, announced that the American Psychiatric Association’s Psychiatric Services journal has published the findings of an expert group aimed at increasing the adoption of digital mental health treatments (DMHTs) within the U.S. healthcare system.

The paper, “Banbury Forum Consensus Statement on the Path Forward for Digital Mental Health Treatment,” was authored by The Banbury Forum for Digital Mental Health Treatment, a group of over 20 international stakeholders including SilverCloud Health and representing healthcare organizations, insurers, employers, patients, researchers, policymakers, digital mental health companies, and the investment community. The Banbury Forum was formed in 2019 to review the current state of evidence and identify the primary challenges to adoption of DMHTs in the U.S. healthcare system, including in response to the challenges COVID-19 presents. The resulting paper identifies the core challenges, as well as opportunities, and provides recommendations to facilitate the successful and sustainable implementation of effective digital mental health interventions in the American healthcare system.

“Through years of rigorous trialing, digital mental health treatments have consistently proven to be effective interventions while also solving the issue of access that many face, yet there is a noticeable gap in adoption, reimbursement and regulation of these treatments within the U.S. healthcare system,” said Banbury Forum member and co-author Derek Richards, Ph.D., Chief Science Officer at SilverCloud Health and Research Fellow at the School of Psychology, Trinity College Dublin.

The paper reports that more than 100 randomized controlled trials demonstrate the effectiveness of DMHTs, and determined DMHTs can effectively overcome access and provider shortage issues that are an inherent part of the U.S. system. Each year, roughly 20% of Americans experience a diagnosable mental health condition, but many don’t receive treatment due to barriers to care, such as stigma and a shortage of mental health providers. For every 100,000 Americans, there are only 30 psychologists and 15.6 psychiatrists, and nearly 120 million Americans reside in designated health professional shortage areas – areas in which the ratio of mental health professionals to residents is smaller than 1 per 30,000 people. The integration of DMHTs into care pathways could improve the efficiency of mental health services and would extend effective treatment to the millions of Americans who are currently unable to access treatment.

“Amid the pandemic, DMHTs are helping to meet the increased demand and reduce the barriers that often prevent people from seeking care in traditional settings, as demand for mental health services – even before the pandemic – has long been higher than supply,” said Ken Cahill, CEO, SilverCloud Health. “We believe now is the time for the power and clinical outcomes of these proven programs to be realized, and our hope is for policymakers and stakeholders to unite in creating a framework that enables the broad adoption of truly effective and proven tools within the U.S. healthcare system.”

“This report makes it clear that for mental health to have parity, digital mental health tools should be an integral part of the U.S. healthcare system, owing to its accessibility and potential impact on mental wellbeing for everyone, regardless of where they live,” said Banbury Forum member and co-author Patricia Areán, Ph.D., Professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine, who co-chaired the forum along with David Mohr, Ph.D., Professor of Preventive Medicine and Director of the Center for Behavioral Intervention Technologies at Northwestern University.

“While there is increasing recognition of the effectiveness of digital mental health treatments in improving common mental health conditions, two principal barriers to broad implementation and adoption were identified,” Mohr said. “Barriers are the absence of reimbursement mechanisms, which for many healthcare systems makes implementation financially unfeasible, and the lack of expertise among decision makers in determining which digital mental health products to use.”

The Banbury Forum was unanimous in making the following actionable recommendations:

Guided DMHTs should be offered as a treatment option to all patients experiencing depression, anxiety disorders, and PTSD.
DMHT products and services should be reimbursable to support integration into the U.S. healthcare landscape.
An evidence standards framework should be developed to support digital formularies and decision making in healthcare organizations, states, and commercial health plans/payers in selecting DMHT products that are effective, safe, and equitable.

About SilverCloud Health

SilverCloud Health is the world’s leading digital mental health company, enabling providers, health plans and employers to deliver clinically validated digital health/therapeutic care that improves outcomes, increases access and scale while reducing costs. The company’s multi-award-winning digital mental health platform is a result of over 18 years of clinical research with leading academic institutions. Today, SilverCloud is being used by over 300 organizations globally to meet their populations’ mental health needs. Global experts have deeply validated the platform through full randomized control trials and real-world data from over 550,000 SilverCloud users. The platform continues to lead the industry with its effectiveness, engagement and range of clinical programs that encompasses the spectrum of mental health needs.

Lyra Health, the leading provider of comprehensive mental health care benefits for employers, today announced a Series E financing round of $187 million. Addition led the round and was joined by new investors Durable Capital Partners LP, Fidelity Management & Research Company, and Baillie Gifford, along with other existing investors. This financing will enable Lyra to further expand its investments in pioneering tech-enabled mental health care, a growing and diverse provider network, and new partnerships to support the world’s largest global organizations.

More than 83% of U.S. employees are experiencing mental health issues, according to research Lyra Health conducted in 2020 in partnership with the National Alliance of Healthcare Purchaser Coalitions. Additionally, 40% of workers feel employers don’t support their mental health.

Transforming Mental Health Care
Lyra more than doubled its customer base in 2020 and extended its services to support more than 2 million members with comprehensive mental health care. Lyra customers include Genentech, a member of the Roche Group; Morgan Stanley; Zoom Video Communications; and dozens of the world’s largest, most respected brands.

Lyra also continues to pioneer new evidence-based, technology-enabled mental health solutions that accelerate access to care and match members to clinically proven programs that prioritize fast and durable symptom improvement. In 2020, the company introduced Lyra Blended Care, which pairs video therapy sessions with personalized digital lessons and exercises based on Cognitive Behavioral Therapy (CBT) principles. Lyra Blended Care is scalable and extensible, leveraging technology to deliver better care quality and clinical outcomes, while reducing the cost of care. In 2020, peer-reviewed Lyra research demonstrated the effectiveness of the Blended Care treatment program for clients with depression and anxiety. Lyra plans to continue expanding Blended Care to serve a wide range of members and mental health challenges.

In 2020, Lyra announced a partnership with Calm, the top mental fitness and resilience application, with more than 90 million downloads to date. Through the partnership, Lyra is making it easier for employers to offer a wide range of mental health tools from a single platform.

“2020 put the need for mental health care transformation in sharp focus, as more people sought help during these extraordinary and difficult times,” said David Ebersman, Lyra Health CEO and co-founder. “The traditional mental health care system cannot address the critical needs people have today. Lyra is now able to directly support more than 2 million members as we enable employers to offer their people easy, effective access to clinically proven mental health care. This latest financing round will allow Lyra to continue to develop new and innovative care solutions while reaching new customers and members.”

About Lyra Health
Lyra Health, a leading provider of innovative mental health benefits for more than 2 million U.S. employees and dependents, is transforming mental health care by creating a frictionless experience for members, providers, and employers. Using matching technology and an innovative digital platform, Lyra quickly connects companies and their employees — plus spouses and children — to world-class therapists, mental health coaches, and personalized medication prescribing. Leading self-insured employers partner with Lyra to tailor value-driven mental health benefits programs specific to their workforce. With Lyra, benefits leaders can offer employees fast, reliable access to providers who practice evidence-based mental health care treatments.

Sentara Halifax Regional Hospital will start construction this month on a new mother, baby and family unit that will transform the experience moms and families have when delivering their baby. The new space will ensure that the birth experience and first days as a mother include the highest quality care in a state-of-the-art unit that provides a safe, supportive environment for the new family.

“This remodel will provide our patients and community with a modern state-of-the-art LDRP unit,” said Brian Zwoyer, president of Sentara Halifax Regional Hospital. “We recognize the importance of comprehensive Women’s Health at Sentara Halifax Regional Hospital and the communities we serve; we are excited to embark on this journey.”

In the past, it was common for moms to move between rooms as they check in at one location, deliver in a separate room, and recover in a third. But now, new mothers and their family members will be able to stay in one place throughout the process, allowing them to settle in and get comfortable as they welcome their bundle of joy into the world.

This unit is equipped with the necessary tools and supplies to care for mother and baby before, during, and after the birth. Most of the time, the baby will get to remain in the room with the mother instead of being taken to the nursery. “The renovation of the rooms to accommodate LDRP is a much anticipated improvement that will enhance our patients’ experience,” said Dr. William Rosche, OBGYN.

While receiving maternity care at Sentara Halifax Regional Hospital, patients have access to highly experienced staff and advanced equipment. The purpose of the LDRP unit is to give the new family a chance to get comfortable, connect with each other and adjust to the changes a baby brings.

“This renovation will bring our unit into the 21st century. It will promote family bonding in a tranquil environment” said, Dr. Joni Abbott, OBGYN .

“This renovation aligns with the Sentara mission, ‘We Improve Health Every day’. We look forward to seeing the completed renovation in the Fall of 2021,” said Zwoyer.

Throughout this remodel you can find regular updates via our Facebook page, Sentara Halifax Regional Hospital, along with some fun contest along the way.

Hull University Teaching Hospitals NHS Trust (HUTH) has been central to the further development of the unique MyPorter software management system aimed at transforming patient flow in hospitals.

MyPorter was developed by porter managers, for porter managers, with its creator GlobalView Systems working with more than 100 NHS Trusts to gain their insight before developing the unique solution. The team at GlobalView worked most closely with Hull University Teaching Hospitals NHS Trust (HUTH) to ensure the software is optimised to suit the reactive, high volume and time critical nature of the tasks carried out by the portering service.

Hull University Teaching Hospitals NHS Trust (HUTH) is a large Acute Trust and one of 27 Major Trauma Centres. HUTH treats around a million patients every year. Based across two hospital sites approximately five miles apart, the portering service underpins the effectiveness of the clinical services throughout the hospital, affecting every aspect and fundamental to providing the very best patient care. With over 20,000 portering tasks carried out each month, if just one in 10 of these were delayed for 15 minutes this would equate to 500 hours in lost portering time each month.

“MyPorter gives us great insight into porter availability, and how long they have been waiting or on task, ensuring tasks can be allocated effectively across the team to improve productivity and the patient experience. The data and insight MyPorter gives us enables us to make the right decisions at the right time.”

Portering provides a vital function within hospitals, without which clinical and non-clinical services cannot operate effectively. MyPorter is a unique task management system, which enables tasks to be allocated, communicated and tracked, with details sent via text message to digital two way radios.

 The system is robust and resilient, providing an independent communications system purpose-built for critical services. Management reports are quickly and readily available, reducing the demand on management time and providing objective information to help plan future service delivery. MyPorter provided HUTH with the insight it needed to be able to adjust shift patterns to align more closely to peaks in demand, meaning more could be achieved with existing portering staff, and the new approach has enabled less reliance on casual worker staffing and over-time.

 The system is proactive; the helpdesk receives notifications before the start time for a task is missed, ensuring reliability of service and alerts to help meet SLAs. Data capture enables paused events, the reason, their duration and their location to be recorded. This makes it easy to identify the causes of delays, and to work with relevant departments to reduce time lost.

Richard Iveson at GlobalView Systems explained; “Portering is a finite resource, and it’s critical that the right levels of resource are in place at the right time. Without this, patient flow can be significantly adversely impacted, potentially delaying treatment and transfers of care, and reducing clinical effectiveness. MyPorter uses data insight and effective reporting to clearly identify when peaks in demand are occurring, and enable resource to be planned accordingly. It can also improve the patient experience, streamlining their movements within the hospital for minimum disruption, and increasing privacy and dignity.”

MyPorter has also improved the patient experience. There is a smoother flow throughout the patient journey, with porters arriving when needed, resulting in fewer delayed or missed appointments, more effective use of essential equipment, and reducing demand on nursing and clinical staff for patient movements.

 “Having a task management system that can quickly and easily identify the nearest available porter in relation to the next task, location and priority is key. It helps to improve the service we deliver to our patients by ensuring they arrive to and from their appointments safely and in good time. It also ensures the team workload is more efficiently managed across our sites.  Our team have full visibility of all  portering activity across our hospital sites including within the Emergency Dept, enabling our service to plan, respond and coordinate resources more effectivley.”

About GlobalView Systems

GlobalView is a UK based software development company, operating across a wide range of verticals including luxury marine, manufacturing, energy and with a specialism in healthcare. Established in 2003, GlobalView takes a highly consultative, collaborative approach, working to understand its customers key challenges and requirements before creating groundbreaking solutions to meet their needs.

Its mission is to create smarter solutions through enhanced communication and an emphasis on data insights and informed decision making.  The MyPorter porter management software is an example of this philosophy, providing ‘useful’ data insight and trend analysis to help improve hospital support services; those that form a vital part of the smooth running of an effective hospital and underpin effective clinical care.

Northwell Health, Illinois’ Lake County, University of Massachusetts Amherst, and Gavi, the Vaccine Alliance, among others are using Salesforce technology to streamline vaccine management

Salesforce announced the launch of Vaccine Cloud technology to help government agencies, healthcare organisations, businesses, non-profits and educational institutions more rapidly, safely and efficiently deploy and manage their vaccine programmes. Current users of Salesforce technology specifically for vaccine administration reportedly include Northwell Health, Illinois’ Lake County, University of Massachusetts Amherst, Gavi, the Vaccine Alliance, and more.

As per a press release, Vaccine Cloud is part of Salesforce’s COVID-19 response technology solutions, which include vaccine inventory management, appointment scheduling, outcome monitoring, public health outreach and more.

Government agencies and public health agencies can reportedly use Vaccine Cloud to monitor their vaccination progress with data and insights, which helps enable them to maximise their programme effectiveness. This includes securing enough doses, monitoring patient outcomes, and making data-driven decisions based on community health needs and risk factors. And, with integration capabilities in Vaccine Cloud, these agencies can bring data from all relevant systems together within the platform, ensuring vaccine data is managed and tracked in one place.

Healthcare provider organisations can use Vaccine Cloud to streamline vaccination processes, such as inventory management, staff training and education, and payment and reimbursement. Vaccine Cloud can also handle all external communication to communities, such as a notification to schedule an initial shot or a reminder to come in for a second dose. And, because it’s built on Salesforce, providers can manage millions of patients across hundreds of sites and care locations with a platform that is efficient, safe and accessible from anywhere, according to the company statement.

Slated from October 7-8, 2021 in Visakhapatnam, the joint effort aims to provide further impetus to indigenous manufacturing of medical devices and bring forward innovations and specialised medical tools and technologies that can attract domestic and global investors

With an objective to draw attention to the growth opportunities and latest developments in the Indian Medical device industry, Messe Frankfurt Trade Fairs India has joined hands with India’s first integrated medical devices manufacturing ecosystem: Andhra Pradesh MedTech Zone (AMTZ).

The joint effort aims to provide further impetus to indigenous manufacturing of medical devices and bring forward innovations and specialised medical tools and technologies that can attract domestic and global investors.

The launch of MedTech Innovation Forum aims to create a collaborative platform for medical device manufacturers, innovators and technology experts to exchange advancements and innovations for the development of the Indian medical device industry, as per a release.

Slated from October 7-8, 2021 in Visakhapatnam, the first edition of this key business event is expected to bring industry leadership together with government and medical consultants to address integral challenges of import dependency, need for technology collaborations as well as medical technology advancements that can be introduced in the industry. The forum has received strong support from apex industry bodies – Association of Indian Medical Device Industry (AIMED) and (Association of Diagnostics Manufacturers of India (ADMI).

Commenting that India’s response and agility in scaling up manufacturing of medical devices together with strong initiatives by the government on making the sector ‘Atmanirbhar’ makes it opportune time to introduce a forum that focuses on bringing medical technology innovations to the forefront, Raj Manek, Managing Director, Messe Frankfurt Trade Fairs India said they are proud to combine strengths with AMTZ in this goal and are confident that the critical insights on MedTech advancements and challenges will enable the sector to create an environment for improved trade and investment opportunities.

The Indian medical devices market, which accounts for more than 1 per cent of the Asia-Pacific (APAC) medical devices market, is expected to grow at a compound annual growth rate of 7.5 per cent through 2025.

Dr Jitendra Sharma, MD & CEO, Andhra Pradesh MedTech Zone elaborated that the industry is poised for significant growth in the next five years, however, it is still largely import-driven with 90 per cent of sophisticated devices being imported from around the world. He believed that the dialogue with medical device manufacturers and innovators will open up opportunities to empower the country’s strong healthcare and medical device industry in the post COVID-19 era.

Dr Sharma further added that AMTZ aims to put the Indian medical device industry on the global map by encouraging sector innovations, and they were happy to join hands with Messe Frankfurt in this endeavour as their expertise and reach across sectors in India will help bring in key stakeholders together.

3D Systems announced its decision to significantly expand its development efforts focused on regenerative medicine and bioprinting solutions. This decision was driven by the tremendous progress made in collaboration with United Therapeutics Corporation and its organ manufacturing and transplantation-focused subsidiary, Lung Biotechnology PBC, on the development of 3D printing systems for solid-organ scaffolds. Leveraging this work as well as accomplishments with additional partners, 3D Systems intends to invest, further develop, and commercialize solutions for the diverse application opportunities in regenerative medicine, including the development of non-solid organ applications requiring biologically sustainable vasculature.

“Human vasculature model created using Print to Perfusion process” (Image courtesy of United Therapeutics)

In 2020, 3D Systems and United Therapeutics achieved significant progress in the development of a next-generation additive manufacturing platform solution for lung scaffolds that is capable of full size, vascularized, rapid, micron-level printing. 3D Systems’ capabilities as a technology innovator, spanning hardware, software, and materials science, combined with United Therapeutics’ renowned expertise in regenerative medicine has enabled advances in lung modeling, 3D printing, as well as material formulation using a unique rhCollagen, and material handling to yield significant capabilities in bioprinters and biomaterials for lung manufacturing. As a result, 3D Systems has built a portfolio of unique capabilities specifically designed to address the requirements of regenerative medicine applications. The newly developed Print to Perfusion™ process enables 3D printing of high-resolution scaffolds which can be perfused with living cells to create tissues. The ability to print large, vascularized, highly detailed hydrogel scaffolds at rapid speeds is now opening new opportunities for a range of tissue applications. To advance these efforts, 3D Systems is expanding its high-speed Figure 4® technology through innovation tailored to bioprinting and regenerative medicine. Building upon these capabilities, the company – in collaboration with its partners – will be able to advance innovation into numerous applications within the human body. The company also believes these capabilities have the potential to enable novel laboratory testing methods to accelerate the development of new drug therapies while reducing the need for animal testing.

“Over the last years as bioprinting and regenerative medicine have evolved, we’ve seen a growing need to place cells at high-resolution in a nurturing matrix to produce complex tissues,” said Chuck Hull, co-founder, executive vice president and chief technology officer, 3D Systems. “Precise 3D printing with hydrogels, followed by perfusion of cells into the printed scaffold is the best way to achieve this, and we are thankful our work with United Therapeutics has given us the opportunity to advance and perfect this technology.”

“Our collaboration with 3D Systems has allowed us to take a first-principles approach to regenerative medicine,” said Derek Morris, associate director of engineering, Lung Biotechnology PBC. “The full size, vascularized lung scaffolds produced by 3D System’s printers allow our cellularization teams to focus on our mission to build an unlimited supply of transplantable organs.”

Building on the progress the company has made to date, 3D Systems is infusing additional resources into its regenerative medicine R&D efforts to accelerate development programs that expand on the scope of potential applications. The company intends to add additional regenerative medicine domain expertise to its team, complementing the deep technology experience and expertise focused on these advanced applications. Additionally, the company is growing its roster of partners to broaden the portfolio of solutions the company offers. 3D Systems previously announced collaborations with CollPlant Biotechnologies (NASDAQ:CLGN) and Antleron that expanded its capabilities in regenerative medicine.

CollPlant is the developer of proprietary recombinant human collagen (rhCollagen) BioInk technology, which is also being used in collaboration with United Therapeutics. Bringing together 3D Systems’ expertise in 3D printing and healthcare and CollPlant’s expertise in rhCollagen-based BioInks will enable joint development of tissue and scaffold bioprinting processes for third party collaborators. As a result, the companies are jointly addressing an unmet market need for a comprehensive solution to produce tissues and scaffolds for regenerative medicine applications.

Antleron co-creates, as an innovation pioneer in the field of regenerative medicine, personalized manufacturing solutions for advanced therapy applications. Antleron integrates core technologies such as 3D printing, bioreactors, and artificial intelligence with bioprocess know-how to enable disruptive manufacturing workflows that convert cells into living therapies. The 3D Systems/Antleron partnership wants to make 3D printing an integrated part of modular and digital factory-of-the-future solutions to enable sustainable and personalized manufacturing of cell & gene therapies, vaccines, tissues, and organs.

3D Systems has delivered additive manufacturing solutions to the healthcare industry for more than 25 years. The company is renowned for its VSP® surgical planning solutions which have enabled the planning of more than 140,000 patient-specific surgical cases, as well as the production of more than two million medical devices from its operations in Littleton, Colorado, and Leuven, Belgium. 3D Systems’ NextDent® 5100 digital dentistry solution is recognized as the industry leader in transforming prosthodontic and orthodontic production at dental laboratories and clinics. The company also has a long-standing relationship with Align Technology, Inc. (NASDAQ:ALGN), the makers of Invisalign clear aligners, iTero scanners, and exocad CAD/CAM services, for which it has co-developed proprietary solutions comprised of customized hardware, software, and non-aligner materials that are used to mass-produce more than 500,000 unique patient-specific aligners per day.

Commenting on the future of regenerative medicine at 3D Systems, Dr. Jeffrey Graves, president and CEO, said, “The progress that Chuck Hull and his team have made over the last three years, in collaboration with the Team from United Therapeutics, has been absolutely remarkable. Through unique developments in new printer hardware, software, and biomaterials technology, they have laid the foundation needed for accelerated commercialization of bioprinting at 3D Systems. Taking a strong application focus we will now expand our commercialization efforts in this nascent industry, which we believe will experience significant growth over the next decade. We expect these efforts to bring substantial benefits to the healthcare patients in critical need, both through direct applications within the human body, as well as in accelerating the development of drug therapies in the pharmaceutical industry. We anticipate regenerative medicine to be an exciting growth driver for our healthcare business over the next decade.”

Multinational firm HCL Technologies is partnering with the University of California (UCLA) in Berkeley to create a lab dedicated to health technology innovations that will meet future healthcare challenges.

The Health Technology Collaborative Laboratory (CoLab), will be housed on the university’s campus in Berkeley. CoLab’s multidisciplinary teams will work on rapid problem-solving, prototyping and testing of breakthrough healthcare technologies. The lab aims to ring together stakeholders in healthcare (patients, clinicians, regulators and insurers), the business community and investors to create and commercialise solutions, from their initial concept through to prototyping, systems architecture and distribution.

As a founding member of the CoLab, HCL is contributing $750,000 over the course of three years.

HCL Technologies provides services and products to organisations around the world through its three business units: IT and Business Services, Engineering and R&D Services, and Products & Platforms. A subsidiary of HCL Enterprise, a company founded in 1976 in India, HCL Technologies operates in 50 countries.

The company has recently provided significant contributions in the US to the CDC Foundation, United Way, Gates Foundation and Feeding America.

“As a responsible global technology leader, we are proud to contribute and support the creation of macro-scale solutions to healthcare issues for a better future for all” said GH Rao, President, Engineering and R&D Services at HCL Technologies.

“We’re honored to support UC Berkeley in this initiative, especially as the healthcare industry is undergoing tremendous transformation. As a founding member, HCL will have the opportunity to contribute to promising solutions and projects underway and looks forward to engaging the CoLab Ecosystem to develop new and unique health technology solutions for the future.”

HealthLynked Corp., a global healthcare network focused on care management of its members and a provider of healthcare technologies that connects doctors, patients and medical data, announced that it will host the first annual Future of Healthcare Summit that will convene the top leaders in the $5 trillion healthcare industry at Arthrex’s corporate campus that features a 30,000-SF fitness center and 200,000-SF Innovation Hotel in Naples, Florida from March 15-17th.

The summit is an invitation only event for healthcare providers. The event features world-class CEOs, innovators and industry experts who will come together to present a series of lectures on a wide range of healthcare topics and explore what can be done to both catalyze innovation and improve healthcare.

Dr. Michael Dent, HealthLynked’s CEO has developed an agenda that focuses on genomics, functional medicine, anti-aging, stem cells, artificial intelligence, diagnostic advances, telemedicine, intellectual property, tissue regeneration, cancer treatments and medical devices.

The summit venue will be open to the public on Tuesday, March 16th, where a series of Ted Talk style lectures will cover the latest healthcare trends, technology, and treatments. This open forum will allow the public the opportunity to learn about the latest advances in healthcare and how they are being applied today and what to expect in future.

HealthLynked has confirmed a world-class slate of speakers including:

Bob Gasparini, Former President NeoGenomics Laboratories
Robert Mino JD, Healthcare Patent Attorney
Michael Dent M.D., Chairman and CEO HealthLynked Corp and Founder NeoGenomics Laboratories
Gagan Babber, Former Co-founder & CTO of Collaborate Cloud
Edwardo Maristany M.D., Naples Center of Functional Medicine

Attendees of the summit include doctors, hospital executives, academics, researchers, venture capitalists, pharmaceutical firms, policymakers, philanthropists, and future leaders. The seating for the summit will follow COVID-19 spacing guidelines and Arthrex campus facilities are equipped with Synexis air purification systems that kill airborne COVID-19 to add an additional layer of safety for the attendees.

For a look at the full agenda, as well as speaker bios, please visit the 2021 Healthcare Summit website. For additional sponsorship opportunities please email summitsponsors@healthlynked.com.

Dr. Michael Dent, Chief Executive Officer of HealthLynked stated, “The next 15 years will bring a wave of medical breakthroughs in new therapies, medicines, medical devices and data analytics. We have achieved new milestones in gene editing, cancer immunotherapy and artificial intelligence. All of these advances will allow us to more effectively treat disease and find cures that have eluded us. Our goal is to provide an informative series of lectures to show the future of healthcare and create an environment for innovate thought leaders to turn ideas into actionable solutions.

About HealthLynked Corp.

HealthLynked Corp. provides a solution for both patient members and providers to improve healthcare through the efficient exchange of medical information. The HealthLynked Network is a cloud-based platform that allows members to connect with their healthcare providers and take more control of their healthcare. Members enter their medical information, including medications, allergies, past surgeries and personal health records, in one convenient online and secure location, free of charge. Participating healthcare providers can connect with their current and future patients through the system. Benefits to in-network providers include the ability to utilize the HealthLynked patent pending patient access hub “PAH” for patient analytics. Other benefits for preferred providers include HLYK marketing tools to connect with their active and inactive patients to improve patient retention, access more accurate and current patient information, provide more efficient online scheduling and to fill last minute cancelations using the Company’s “real time appointment scheduling” all within its mobile application. Preferred providers pay a monthly fee to access these HealthLynked services. For additional information about HealthLynked Corp.